Ventana Biotech Stock Debt To Equity
| VNTA Stock | USD 0 0 41.67% |
Ventana Biotech fundamentals help investors to digest information that contributes to Ventana Biotech's financial success or failures. It also enables traders to predict the movement of Ventana Pink Sheet. The fundamental analysis module provides a way to measure Ventana Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ventana Biotech pink sheet.
Ventana |
Ventana Biotech Company Debt To Equity Analysis
Ventana Biotech's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Ventana Biotech has a Debt To Equity of 0.0%. This is 100.0% lower than that of the Financial Services sector and about the same as Shell Companies (which currently averages 0.0) industry. The debt to equity for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Portfolio Manager Now
Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital |
| All Next | Launch Module |
Ventana Fundamentals
| Current Valuation | 165.2 K | |||
| Shares Outstanding | 55.07 M | |||
| Price To Earning | (1.00) X | |||
| Gross Profit | (260) | |||
| EBITDA | (36.71 K) | |||
| Net Income | (47.08 K) | |||
| Current Ratio | 0.02 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (54.01 K) | |||
| Earnings Per Share | (0) X | |||
| Beta | -2.08 | |||
| Market Capitalization | 192.73 K |
About Ventana Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ventana Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ventana Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ventana Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Ventana Pink Sheet
Ventana Biotech financial ratios help investors to determine whether Ventana Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ventana with respect to the benefits of owning Ventana Biotech security.